Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2007

Crucell Inks Research License Agreement with ProFibrix on STAR

  • Crucell entered into a nonexclusive STAR® research license agreement with ProFibrix covering the production of specific forms of human fibrinogen.

    According to Crucell, STAR technology is a production method that is particularly useful for the production of recombinant human antibodies and proteins.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »